203 related articles for article (PubMed ID: 31182782)
21. High expression of inositol 1,4,5-trisphosphate receptor, type 2 (ITPR2) as a novel biomarker for worse prognosis in cytogenetically normal acute myeloid leukemia.
Shi JL; Fu L; Wang WD
Oncotarget; 2015 Mar; 6(7):5299-309. PubMed ID: 25779662
[TBL] [Abstract][Full Text] [Related]
22. Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects.
Wellbrock J; Latuske E; Köhler J; Wagner K; Stamm H; Vettorazzi E; Vohwinkel G; Klokow M; Uibeleisen R; Ehm P; Riecken K; Loges S; Thol F; Schubert C; Amling M; Jücker M; Bokemeyer C; Heuser M; Krauter J; Fiedler W
Clin Cancer Res; 2015 May; 21(10):2388-98. PubMed ID: 25745035
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.
Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y
Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889
[TBL] [Abstract][Full Text] [Related]
24. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.
Gönen M; Sun Z; Figueroa ME; Patel JP; Abdel-Wahab O; Racevskis J; Ketterling RP; Fernandez H; Rowe JM; Tallman MS; Melnick A; Levine RL; Paietta E
Blood; 2012 Sep; 120(11):2297-306. PubMed ID: 22855599
[TBL] [Abstract][Full Text] [Related]
25. Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML.
Carter BZ; Qiu Y; Huang X; Diao L; Zhang N; Coombes KR; Mak DH; Konopleva M; Cortes J; Kantarjian HM; Mills GB; Andreeff M; Kornblau SM
Blood; 2012 Jul; 120(1):173-80. PubMed ID: 22645176
[TBL] [Abstract][Full Text] [Related]
26. Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.
Nii T; Prabhu VV; Ruvolo V; Madhukar N; Zhao R; Mu H; Heese L; Nishida Y; Kojima K; Garnett MJ; McDermott U; Benes CH; Charter N; Deacon S; Elemento O; Allen JE; Oster W; Stogniew M; Ishizawa J; Andreeff M
Leukemia; 2019 Dec; 33(12):2805-2816. PubMed ID: 31127149
[TBL] [Abstract][Full Text] [Related]
27. TNFAIP8 promotes AML chemoresistance by activating ERK signaling pathway through interaction with Rac1.
Pang Y; Zhao Y; Wang Y; Wang X; Wang R; Liu N; Li P; Ji M; Ye J; Sun T; Li J; Ma D; Lu F; Ji C
J Exp Clin Cancer Res; 2020 Aug; 39(1):158. PubMed ID: 32795319
[TBL] [Abstract][Full Text] [Related]
28. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.
Haubner S; Perna F; Köhnke T; Schmidt C; Berman S; Augsberger C; Schnorfeil FM; Krupka C; Lichtenegger FS; Liu X; Kerbs P; Schneider S; Metzeler KH; Spiekermann K; Hiddemann W; Greif PA; Herold T; Sadelain M; Subklewe M
Leukemia; 2019 Jan; 33(1):64-74. PubMed ID: 29946192
[TBL] [Abstract][Full Text] [Related]
29.
Zhang TJ; Zhou JD; Zhang W; Lin J; Ma JC; Wen XM; Yuan Q; Li XX; Xu ZJ; Qian J
Clin Epigenetics; 2018; 10():47. PubMed ID: 29643943
[TBL] [Abstract][Full Text] [Related]
30. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.
Gentles AJ; Plevritis SK; Majeti R; Alizadeh AA
JAMA; 2010 Dec; 304(24):2706-15. PubMed ID: 21177505
[TBL] [Abstract][Full Text] [Related]
31. Calcitonin gene-related peptide receptor Calcrl is enriched in hair follicles stem cells and differentially expressed in interfollicular epidermis in murine skin.
Gong Y; Wei JP; Wang TH; Zhong HB; Liao XH
Neuroreport; 2020 Aug; 31(11):814-818. PubMed ID: 32576770
[TBL] [Abstract][Full Text] [Related]
32. Identification of novel molecular markers for prognosis estimation of acute myeloid leukemia: over-expression of PDCD7, FIS1 and Ang2 may indicate poor prognosis in pretreatment patients with acute myeloid leukemia.
Tian Y; Huang Z; Wang Z; Yin C; Zhou L; Zhang L; Huang K; Zhou H; Jiang X; Li J; Liao L; Yang M; Meng F
PLoS One; 2014; 9(1):e84150. PubMed ID: 24416201
[TBL] [Abstract][Full Text] [Related]
33. A parsimonious 3-gene signature predicts clinical outcomes in an acute myeloid leukemia multicohort study.
Wagner S; Vadakekolathu J; Tasian SK; Altmann H; Bornhäuser M; Pockley AG; Ball GR; Rutella S
Blood Adv; 2019 Apr; 3(8):1330-1346. PubMed ID: 31015209
[TBL] [Abstract][Full Text] [Related]
34. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
Alachkar H; Santhanam R; Harb JG; Lucas DM; Oaks JJ; Hickey CJ; Pan L; Kinghorn AD; Caligiuri MA; Perrotti D; Byrd JC; Garzon R; Grever MR; Marcucci G
J Hematol Oncol; 2013 Mar; 6():21. PubMed ID: 23497456
[TBL] [Abstract][Full Text] [Related]
35. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
36. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
[TBL] [Abstract][Full Text] [Related]
37. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
38. Relative receptor tyrosine kinases and anti-apoptotic transcripts hold potential for predicting inferior outcome in adult acute myeloid leukemia: a prospective pilot study.
Sharawat SK; Vishnubhatla S; Bakhshi R; Raina V; Kumar L; Sharma A; Bakhshi S
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):501-508.e2. PubMed ID: 25065779
[TBL] [Abstract][Full Text] [Related]
39. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
[TBL] [Abstract][Full Text] [Related]
40. Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
Fernandez S; Desplat V; Villacreces A; Guitart AV; Milpied N; Pigneux A; Vigon I; Pasquet JM; Dumas PY
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
